CytomX Therapeutics, Inc. (Nasdaq: CTMX) has recently reported its first quarter 2024 financial results and provided a business update. The company announced positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors. Additionally, the first dose cohort has been cleared in the Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY ADC, in solid tumors, with initial data anticipated in the first half of 2025. Activities for the Phase 1 study initiation for CX-801, an interferon alpha-2b PROBODY cytokine, are ongoing, including a clinical collaboration agreement with Merck for evaluation in combination with KEYTRUDA (pembrolizumab).

The company has also achieved $10 million in milestones under a T-cell engaging bispecific collaboration with Astellas for preclinical progress on the first two programs in the collaboration. Dr. Zhen Su has been appointed to the Board of Directors, and management will hold a conference call today at 5 p.m. EDT / 2 p.m. PDT to discuss these updates.

Sean McCarthy, D.Phil., the chief executive officer and chairman of CytomX, expressed optimism about the company’s progress, stating, “CytomX’s multi-modality PROBODY therapeutic pipeline encompasses some of the most exciting areas of current oncology R&D, including T-cell engagers, ADCs, and cytokines. CytomX’s leadership and continuous innovation in the field of masked, conditionally activated biologics ideally positions us to develop novel, potent therapies for cancer patients in key areas of unmet need.” McCarthy further highlighted that the company is executing its plan for 2024 with substantial momentum and is looking forward to key data readouts from their multi-modality PROBODY therapeutic pipeline in the coming months.

Overall, CytomX’s recent developments underscore its commitment to advancing innovative therapies in the field of oncology, with a focus on addressing critical unmet medical needs for cancer patients.